ASH 2019: Interferon-Alfa Treatment Offers Best ... - MPN Voice
ASH 2019: Interferon-Alfa Treatment Offers Best Outcomes in Polycythemia Vera
![Manouche profile image](https://images.hu-production.be/avatars/a3b96d3f503b47bbbcb94ae844837ba1_small@2x_100x100.jpg)
Written by
![Manouche profile image](https://images.hu-production.be/avatars/a3b96d3f503b47bbbcb94ae844837ba1_small@2x_100x100.jpg)
Manouche
To view profiles and participate in discussions please or .
3 Replies
•
« This is the first time that interferon has been shown to improve survival in patients with polycythemia vera, compared with phlebotomy only or [hydroxyurea], as well as significantly increasing the time to develop myelofibrosis »
“For years, there has been argument whether patients should be treated with phlebotomy only or, if cytoreduction therapy is needed, should it be [hydroxyurea] or interferon?” said Dr. Silver. “We believe the latter, as do many others, since interferon has biologic reasons for its use in polycythemia vera. It is not a nonspecific cell poison like [hydroxyurea].”
Not what you're looking for?
You may also like...
Ropeginterferon Alfa-2b listed as Preferred Treatment in Polycythemia Vera
ropeginterferon alfa-2b-njft as a preferred treatment option for patients with high- and low-risk...
Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
results suggest the benefits of treatment with ropeginterferon alfa-2b-njft outweigh the costs for a
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment
dosing regimen of 250-350-500 µg of ropeginterferon alfa-2b is well-tolerated and highly...
FDA Rejects Ropeginterferon alfa-2b for Polycythemia Vera
information. »...
FDA Issues Complete Response Letter for Ropeginterferon Alfa-2b for Polycythemia Vera
ropeginterferon alfa-2b-njft for the treatment of patients with polycythemia vera »...